Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

20 Apr 2023

Abstract excerpt

Abstract Background Patients with acute myeloid leukemia (AML) who have tumor protein p53 (TP53) mutations or a complex karyotype have a poor prognosis, and hypomethylating agents are often used. The authors evaluated the efficacy of entospletinib, an oral inhibitor of spleen tyrosine kinase, combined with decitabine in this patient population. Methods This was a multicenter, open‐label, phase 2 substudy of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37078412
DOI: 10.1002/cncr.34780

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialPMID 37078412Read ↗

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.Semantic proximity Read ↗

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read ↗

What have we learned about TP53-mutated acute myeloid leukemia?Semantic proximity Read ↗

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.Semantic proximity Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of TP53 mutations in a real-world setting.Semantic proximity Read ↗

Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.Semantic proximity Read ↗

Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype.Semantic proximity Read ↗

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical DevelopmentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.